Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 May;105(9):686-692.
doi: 10.1136/heartjnl-2018-314216. Epub 2019 Jan 30.

Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies

Affiliations
Meta-Analysis

Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies

Ahmad Jayedi et al. Heart. 2019 May.

Abstract

Objective: To systematically assess the association of circulating inflammation markers with the future risk of hypertension.

Methods: We did a systematic literature search of PubMed and Scopus, from database inception to July 10, 2018. Prospective and retrospective cohort studies evaluating the association of circulating C reactive protein (CRP), high-sensitive CRP (hs-CRP), interleukin 6 (IL-6) and IL-1β to the risk of developing hypertension in the general population were included. The relative risks (RRs) for the top versus bottom tertiles of circulating biomarkers were calculated using a fixed-effects/random-effects model. A potential non-linear dose-response association was tested.

Results: Fourteen prospective cohort studies, two retrospective cohort studies and five nested case-control studies involving 142 640 participants and 20 676 cases were identified. The RR for the third versus first tertiles of circulating CRP was 1.23 (95% CI 1.11 to 1.35; I2=59%, n=12). The association remained unchanged after adjustment for body mass index. The RRs for other biomarkers were as follows: hs-CRP (RR 1.20, 95% CI 1.02 to 1.37; I2=74%, n=7), IL-6 (RR 1.51, 95% CI 1.30 to 1.71; I2=0%, n=5), and IL-1β (RR 1.22, 95% CI 0.92 to 1.51; I2=0%, n=3). A non-linear dose-response meta-analysis demonstrated that the risk of hypertension increased linearly with increasing circulating inflammation markers, even within the low-risk and intermediate-risk categories.

Conclusions: Higher levels of circulating CRP, hs-CRP and IL-6, but not IL-1β, were associated with the risk of developing hypertension. The association persisted in subgroups of studies defined by major sources of heterogeneity.

Keywords: hypertension; inflammatory markers; meta-analysis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Relative risk of hypertension for the top versus bottom tertiles of circulating inflammation markers (A) C reactive protein. (B) High-sensitive C reactive protein. (C) IL-6. ES: effect size.
Figure 2
Figure 2
Dose-response associations between circulating inflammation markers and risk of developing hypertension. CRP, C reactive protein; hs-CRP, high-sensitive C reactive protein.

Comment in

Similar articles

Cited by

References

    1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217–23. - PubMed
    1. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013;310:959–68. - PubMed
    1. De Miguel C, Rudemiller NP, Abais JM, et al. Inflammation and hypertension: new understandings and potential therapeutic targets. Curr Hypertens Rep 2015;17:507. - PMC - PubMed
    1. Bautista LE, López-Jaramillo P, Vera LM, et al. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001;19:857–61. - PubMed
    1. Bautista LE, Vera LM, Arenas IA, et al. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005;19:149–54. - PubMed

Publication types